ORUKA THERAPEUTICS INC (ORKA)
Sector: Health Care
2026 Annual Meeting Analysis
ORUKA THERAPEUTICS INC · Meeting: June 2, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors for terms expiring in 2029
Dr. Klein joined the board in August 2024 (less than 24 months ago), making him exempt from the TSR underperformance trigger under policy; he has strong and directly relevant biotechnology leadership experience as CEO of Oruka, and no overboarding, attendance, independence, or familial relationship concerns are present.
Mr. Martin was appointed to the board in December 2025 (well within the 24-month new-director exemption window), has directly relevant commercial biopharmaceutical experience, no overboarding concerns, and no other policy triggers apply.
Both Class II nominees pass all policy screens: neither triggers the TSR underperformance test (both joined within the last 24 months and are therefore exempt), neither is overboarded, both have relevant industry experience, and there are no attendance, independence, or familial relationship concerns. The stock's 3-year return of +423.5% dramatically outperforms the XBI — SPDR S&P Biotech ETF's 3-year return of +71.4% by +352.1 percentage points, which far exceeds the 65-percentage-point threshold required to trigger a concern even if tenure were longer — further reinforcing a FOR vote on the full slate.
Say on Pay
✓ FORCEO
Lawrence Klein
Total Comp
$3,356,050
Prior Support
N/A
CEO Lawrence Klein's total compensation of $3,356,050 is reasonable for a biotech CEO at a $3.4 billion market cap company, with a pay mix that is heavily weighted toward variable compensation — base salary of $624,000 represents approximately 19% of total pay, well below the 40% fixed-pay ceiling, and the remainder consists of stock options (68%) and a performance-based cash bonus (13%). The 2025 annual bonus was tied to measurable clinical development milestones for ORKA-001 and ORKA-002, and the Compensation Committee determined achievement at 130% of target based on documented outperformance of those goals, which is consistent with the company's stock delivering a one-year return of +700.5% versus the XBI — SPDR S&P Biotech ETF's +85.3%. The company maintains a Nasdaq-compliant clawback policy, no prior Say on Pay vote result is available to evaluate, and no individual executive appears to be materially above benchmark for a company of this stage and size.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
2 yrs
Audit Fees
$1,050,000
Non-Audit Fees
$2,000
PwC was engaged as Oruka's auditor at the Merger Closing in August 2024, giving it a tenure of approximately two years — well below the 25-year threshold that would raise independence concerns. Non-audit fees of $2,000 (an online resource library subscription) represent less than 0.2% of audit fees of $1,050,000, far below the 50% ratio that would trigger a negative vote. PwC is a Big 4 firm fully appropriate for a company of Oruka's size and complexity, and no material restatements have been disclosed.
Overall Assessment
The 2026 Oruka Therapeutics annual meeting presents a clean ballot with three standard proposals — director elections, auditor ratification, and Say on Pay — all of which pass policy screens and receive a FOR determination. The company's stock has dramatically outperformed the XBI — SPDR S&P Biotech ETF benchmark over the past year and three years, both director nominees are within the 24-month new-director exemption window, PwC's tenure is short and fees are almost entirely for audit services, and executive pay is structured with appropriate performance linkage.